Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...

University of California, Berkeley, researchers have made a major improvement in CRISPR-Cas9 technology that achieves an unprecedented success rate of 60 percent when replacing a short stretch of DNA ...

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug ...

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

In a decision announced today (March 26), the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (USPTO and ...

CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...

Crispr Therapeutics AG's partnership with Vertex Pharmaceuticals offers financial support, mentorship, and validation, enhancing Crispr's approach and technology. Despite slower-than-expected Casgevy ...